https://www.selleckchem.com/pr....oducts/pacritinib-sb
BACKGROUND This study aimed to analyze pathologic characteristics, treatment, prognosis, and tumor EGFR and ALK mutation proportion of non-small cell lung cancer (NSCLC) patients aged less then 40 years at diagnosis. METHODS We retrospectively reviewed data of NSCLC patients diagnosed at Taipei Veterans General Hospital (TPEVGH) between June 2007 and December 2014, aged less than 90 year at the time of the diagnosis. RESULTS We found 5,051 cases of NSCLC, including 168 patients who were younger than 40 years (younger group) an
إعجاب
علق
شارك
